MedPath

Evaluation of Eye Health Benefits of Black Tomato Extract

Not Applicable
Completed
Conditions
High Myopia
Eye
Registration Number
NCT06412393
Lead Sponsor
TCI Co., Ltd.
Brief Summary

Verification of the efficacy of black tomato extract for eye health.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
56
Inclusion Criteria
  • Age greater than 20 and capable of providing informed consent.
  • Daily usage of 3C (computer, communication, and consumer electronics) for more than 6 hours (OSDI screening - those experiencing dryness and fatigue in the eyes).
  • BMI between 22 and 35.
  • High myopia population (-5.00 to -9.00D)
Exclusion Criteria
  • History of any eye surgery (e.g., strabismus surgery, refractive surgery).
  • Presence of systemic diseases affecting the anterior surface of the eye.
  • Long-term use of medications affecting the anterior surface of the eye.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Grading of Retinal Vascular DiameterChange from Baseline at 8 weeks

Measurement of Grading of Retinal Vascular Diameter using a fundus camera.

Positive Relative Accommodation (PRA)Change from Baseline at 8 weeks

Measurement of Positive Relative Accommodation using a phoropter.

Accommodative FacilityChange from Baseline at 8 weeks

Measurement of Accommodative Facility using a Flipper lens ±2.00D.

Positive Fusional Vergence (PFV)Change from Baseline at 8 weeks

Measurement of Positive Fusional Vergence using a phoropter.

Intraocular Pressure Measurement (IOP)Change from Baseline at 8 weeks

Measurement of Intraocular Pressure using a non-contact tonometer. Unit: mmHg

Visual Contrast Sensitivity FunctionChange from Baseline at 8 weeks

Perform the Visual Contrast Sensitivity Test (Distance and near) under environmental illumination/dark/bright conditions.

Negative Fusional Vergence (NFV)Change from Baseline at 8 weeks

Measurement of Negative Fusional Vergence using a phoropter.

Negative Relative Accommodation (NRA)Change from Baseline at 8 weeks

Measurement of Negative Relative Accommodation using a phoropter.

Secondary Outcome Measures
NameTimeMethod
Best-corrected visual acuityChange from Baseline at 8 weeks

Measurement of Best-corrected visual acuity (distance and near) using a logMAR chart.

The change of Endothelin-1 (ET-1)Change from Baseline at 8 weeks

Fasting venous blood will be sampled to measure concentrations of ET-1.

The change of Tumor necrosis factor-α (TNF-α)Change from Baseline at 8 weeks

Fasting venous blood will be sampled to measure concentrations of TNF-α.

Questionnaire Survey - Ocular Surface Disease Index (OSDI)Change from Baseline at 8 weeks

The OSDI is assessed on a scale of 0 to 100, with higher scores representing greater disability.

Trial Locations

Locations (1)

Chung Shan Medical University

🇨🇳

Taichung, Taiwan

Chung Shan Medical University
🇨🇳Taichung, Taiwan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.